Share on StockTwits

Halozyme Therapeutics (NASDAQ:HALO) was the recipient of a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 15,117,970 shares, an increase of 10.6% from the April 15th total of 13,666,028 shares, Analyst Ratings Network reports. Currently, 15.2% of the company’s shares are short sold. Based on an average daily volume of 1,442,355 shares, the short-interest ratio is presently 10.5 days.

A number of research firms have recently commented on HALO. Analysts at Citigroup Inc. initiated coverage on shares of Halozyme Therapeutics in a research note on Tuesday, April 15th. They set a “buy” rating and a $12.00 price target on the stock. Analysts at BMO Capital Markets reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, April 4th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Halozyme Therapeutics currently has an average rating of “Buy” and an average price target of $11.50.

Halozyme Therapeutics (NASDAQ:HALO) opened at 7.95 on Thursday. Halozyme Therapeutics has a one year low of $5.88 and a one year high of $18.18. The stock’s 50-day moving average is $8.4 and its 200-day moving average is $12.88. The company’s market cap is $905.5 million.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.08. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $13.37 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, analysts predict that Halozyme Therapeutics will post $-0.55 earnings per share for the current fiscal year.

Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.